Huang YH, Zhi-yi Zhang C, Huang QS, et al. - As little is known about EBV-associated intrahepatic cholangiocarcinoma (EBVaICC), so researchers comprehensively examined its clinicopathology, tumor immune microenvironment (TIME) and genomic landscape in southern China. They assessed 303 intrahepatic cholangiocarcinomas (ICCs) using in situ hybridization for EBV and compared clinicopathological parameters between EBVaICC and nonEBVaICC. According to results, EBVaICC accounted for 6.6% of ICCs, with EBV latency type I infection and clonal EBV isolates form. Female predominance, younger patient predominance, solitary tumor, higher HBV infection rate, lower cirrhotic background, and increased lymphoepithelioma-like subtype proportion were distinctive clinicopathological features of EBVaICC. Findings suggested that EBVaICC, as a subset of ICC, has unique etiological features, clinicopathology and molecular genetics with a significantly larger TIME component. The majority of cases belong to TMIT I, though candidates for immune checkpoint therapy may be patients with EBVaICC.